Table 1.
Pain-impeded activities of daily living among the respondents of GE surveys, from 2014 to 2017.
| 2014 (n = 9516) | 2015 (n = 9358) | 2016 (n = 9165) | 2017 (n = 9826) | ||
|---|---|---|---|---|---|
| Pain impeded activities of daily living | |||||
| Not at all | No./Total No. (%) | 2287/5119 (44.7) | 2191/5021 (43.6) | 2117/4947 (42.8) | 2330/5257 (44.3) |
| aRR (95% CI)* | 1 (reference) | 0.97 (0.92–1.03) | 0.96 (0.90–1.02) | 1.00 (0.95–1.06) | |
| Somewhat | No./Total No. (%) | 1857/5119 (36.3) | 1861/5021 (37.1) | 1819/4947 (36.8) | 1923/5257 (36.6) |
| aRR (95% CI)* | 1 (reference) | 1.02 (0.96–1.09) | 1.01 (0.95–1.08) | 1.01 (0.94–1.07) | |
| Moderate | No./Total No. (%) | 516/5119 (10.1) | 502/5021 (10.0) | 511/4947 (10.3) | 506/5257 (9.6) |
| aRR (95% CI)* | 1 (reference) | 1.00 (0.88–1.13) | 1.02 (0.91–1.16) | 0.94 (0.83–1.06) | |
| Much and extreme | No./Total No. (%) | 459/5119 (9.0) | 467/5021 (9.3) | 500/4947 (10.1) | 498/5257 (9.5) |
| aRR (95% CI)* | 1 (reference) | 1.04 (0.91–1.18) | 1.12 (0.99–1.28) | 1.04 (0.91–1.18) | |
| Missing | No. (%) | 4397 (46.2) | 4337 (46.3) | 4218 (46.0) | 4569 (46.5) |
| aRR (95% CI)* | 1 (reference) | 1.01 (0.97–1.06) | 1.01 (0.97–1.05) | 1.02 (0.98–1.06) | |
aRR, adjusted risk ratio; CI, confidence interval; GE, Health Interview Survey; NSAIDs, nonsteroidal anti-inflammatory drugs.
*Adjusted for age and sex with direct standardization; 2014 cohort was selected as a reference population in the GE survey.